Monday, 21 Oct 2019

You are here

Bimekizumab Add-on Therapy in Rheumatoid Arthritis

Bimekizumab is a dual inhibitor of IL-17A and IL-17F that has been shown to be effective in psoriasis and psoriatic arthritis. A proof-of-concept study shows that giving bimekizumab to rheumatoid arthritis (RA) patients not adequately controlled by certolizumab pegol (CZP) resulted in a rapid decrease in disease activity achieved after 12 weeks of treatment. These findings are novel as anti-IL-17 monoclonal antibody therapy has previously been shown to be ineffective in RA. 

This phase 2a, double-blind, proof-of-concept study enrolled 159 patients with moderate-to-severe RA who had active disease after 8 weeks of open-label CZP treatment.  There were 79 incomplete responders who continued their CZP but were randomized to either placebo or bimekizumab (240 mg loading dose then 120 mg Q2W). The primary endpoints was the change in DAS28(CRP) at week 20. 

By week 20, there was a greater reduction in DAS28(CRP) in the CZP-IR plus bimekizumab group compared with the CZP-IR plus placebo group (61% vs 48%). The decrease in DAS28(CRP) was -1.41 for the BIM+CZP group vs. -0.82 for the CZP+PBO group. 

There were more overall infections (TEAEs) with CZP plus bimekizumab (50.0%) compared to CZP plus placebo (22.2%). There was only one serious infection in each group by study end. 

These results suggest the possible utility of a dual IL-17 inhibitor, bimekizumab, in RA patients not responding to TNF inhibition. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

Which insurance carrier will agree to pay for the COST of certolizumab pegol (CZP) PLUS bimekizumab ? Why not use MTX before using bimekizumab ? or use low dose steroids? Dr. NAC

More Like This

Stress and the Risk of Incident Inflammatory Arthritis

A prospective analysis of newly diagnosed, inflammatory arthritis (IA) patients suggests that perceived distress (stress) increases the odds of incident IA.

Juvenile Arthritis at Risk for Coronary Artery Disease

Arthritis Care & Research reports that juvenile arthritis (JA) patients may have a higher risk if coronary artery disease (CAD) in adulthood. 

Data was drawn from the National Health and Nutrition Examination (2007‐2014).  The diagnoses of JA and CAD were self declared by respondents.

Long Delays for Inflammatory Arthritis Patients

The National Rheumatoid Arthritis Society's (NRAS) annual audit has identified significant treatment delays for patients with suspected early inflammatory arthritis could result in unnecessary harm. 

Antibiotics Increase Rheumatoid Risk - Again

Another UK study has suggested that prior use of antibiotics increases the risk of developing rheumatoid arthritis (RA).

Rheumatology has published a 15 year case–control study that compared 8482 newly diagnosed RA patients and 22,661 controls from the UK’s Royal College of General Practitioners Research and Surveillance Centre database (between 2006 and 2018).

Two vs. Four Weeks of Antibiotic Therapy in Septic Arthritis

A prospective trial has shown that 2 weeks of antibiotic therapy is as effective as 4 weeks of antibiotic therapy, with similar outcomes but shorter hospital stays.

This Swiss study was a prospective, unblinded, randomised, non-inferiority study comparing either 2 or 4 weeks of antibiotic therapy after surgical drainage of native joint bacterial arthritis in adults.